Schöll, Michael

Head-to-head comparison of tau positron emission tomography tracers [18F]flortaucipir and [18F]RO948

Smith, R., Schöll, M., Leuzy, A., Jögi, J., Ohlsson, T., Strandberg, O., & Hansson, O. (2020) · European Journal of Nuclear Medicine and Molecular Imaging

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 88

Synaptic vesicle protein 2A as a potential biomarker in synaptopathies

Heurling, K., Ashton, N. J., Leuzy, A., Zimmer, E. R., Blennow, K., Zetterberg, H., Eriksson, J., Lubberink, M., & Schöll, M. (2019) · Molecular and Cellular Neuroscience

Alzheimer's disease research and treatmentsNeuroscience and Neuropharmacology Research

Cited by 77

A scoping review of remote and unsupervised digital cognitive assessments in preclinical Alzheimer's disease

Polk, S. E., Öhman, F., Hassenstab, J., König, A., Papp, K. V., Schöll, M., & Berron, D. (2025) · npj Digital Medicine

Dementia and Cognitive Impairment ResearchHistorical and Modern Theater Studies

Cited by 73

Tau neuropathology correlates with FDG-PET, but not AV-1451-PET, in progressive supranuclear palsy.

Smith, R., Schöll, M., Honer, M., Nilsson, C. F., Englund, E., & Hansson, O. (2017) · Acta Neuropathologica

Alzheimer's disease research and treatmentsParkinson's Disease Mechanisms and Treatments

Cited by 62

Differential effects of APOE2 and APOE4 alleles on PET‐measured amyloid‐β and tau deposition in older individuals without dementia: Neuroimaging / imaging and genetics

Grothe, M. J., Salvadó, G., Groot, C., Moscoso, A., Gispert, J. D., Schöll, M., & Ossenkoppele, R. (2020) · Alzheimer's & Dementia

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 3